Method of treating airway diseases with β-adrenergic inverse agonists
First Claim
Patent Images
1. A method for treatment of pulmonary airway disease in a subject suffering from pulmonary airway disease comprising chronically administering a therapeutically effective amount of a β
- -adrenergic inverse agonist to the subject to treat the pulmonary airway disease by action of inverse agonism to promote long-term upregulation of the population of β
-adrenergic receptors upon chronic administration of the β
-adrenergic inverse agonist, wherein the β
-adrenergic inverse agonist exhibits inverse agonist activity at the β
2 receptor of bronchial tissue, wherein the β
-adrenergic inverse agonist is selected from the group consisting of nadolol, bupranolol, butoxamine, carazolol, ICI-118,551, levobunolol, metoprolol, and timolol, and wherein such chronic administration requires increasing dosages over time.
4 Assignments
0 Petitions
Accused Products
Abstract
The use of β-adrenergic inverse agonists provides a new and highly efficient way of treating a number of pulmonary airway diseases, including asthma, emphysema, and chronic obstructive pulmonary diseases. In general, such a method comprises administering a therapeutically effective amount of a β-adrenergic inverse agonist to the subject to treat the pulmonary airway disease. Particularly preferred inverse agonists include nadolol and carvedilol.
41 Citations
18 Claims
-
1. A method for treatment of pulmonary airway disease in a subject suffering from pulmonary airway disease comprising chronically administering a therapeutically effective amount of a β
- -adrenergic inverse agonist to the subject to treat the pulmonary airway disease by action of inverse agonism to promote long-term upregulation of the population of β
-adrenergic receptors upon chronic administration of the β
-adrenergic inverse agonist, wherein the β
-adrenergic inverse agonist exhibits inverse agonist activity at the β
2 receptor of bronchial tissue, wherein the β
-adrenergic inverse agonist is selected from the group consisting of nadolol, bupranolol, butoxamine, carazolol, ICI-118,551, levobunolol, metoprolol, and timolol, and wherein such chronic administration requires increasing dosages over time. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)
- -adrenergic inverse agonist to the subject to treat the pulmonary airway disease by action of inverse agonism to promote long-term upregulation of the population of β
Specification